Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: A randomised crossover trial

Diabetologia

Volumn 52, Issue 1, 2009, Pages 46-49

  Schjoedt, K J ^a   Astrup, A S ^a   Persson, F ^a   Frandsen, E ^b   Boomsma, F ^c   Rossing, K ^a   Tarnow, L ^a   Rossing, P ^a   Parving, H H ^d,e  

^a STENO DIABETES CENTER   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

ACE inhibitor; Albuminuria; Diabetic nephropathy; Lisinopril; Optimal dose; Renoprotection; Type 1 diabetes

Indexed keywords

ALBUMIN; CREATININE; FUROSEMIDE; LISINOPRIL;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PROTECTIVE AGENTS;

EID: 57249089007     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-008-1184-8     Document Type: Article

References (10)

1. Parving H-H, Mauer M, Ritz E (2004) Diabetic nephropathy. In: Brenner BM (ed) The kidney, 7th edn. Saunders, Philadelphia, pp 1777-1818
2. VJ Cirillo HJ Gomez J Salonen 1988 Lisinopril: dose-peak effect relationship in essential hypertension Br J Clin Pharmacol 25 533 538
3. HJ Gomez VJ Cirillo JA Sromovsky 1989 Lisinopril dose-response relationship in essential hypertension Br J Clin Pharmacol 28 415 420
4. KJ Schjoedt K Rossing TR Juhl 2006 Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy Kidney Int 70 536 542
5. AS Levey J Coresh T Greene 2006 Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 145 247 254
6. K Rossing KJ Schjoedt BR Jensen F Boomsma H-H Parving 2005 Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 1190 1198
7. NK Hollenberg H-H Parving G Viberti 2007 Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus J Hypertens 25 1921 1926
8. S Yusuf KK Teo J Pogue 2008 Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 1547 1559
9. GD Laverman G Navis RH Henning PE de Jong D de Zeeuw 2002 Dual rennin-angiotensin system blockade at optimal doses for proteinuria Kidney Int 62 1020 1025
10. P Ruggenenti N Mise R Pisoni 2003 Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies Circulation 107 586 592